TEVA financial statements
The full income statement, balance sheet, and cash-flow statement for Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 17.3B YoY+4.3% | 16.5B YoY+4.4% | 15.8B YoY+6.2% | 14.9B YoY-6.0% | 15.9B YoY-4.7% | |
8.94B YoY+10.8% | 8.06B YoY+5.5% | 7.64B YoY+9.6% | 6.97B YoY-8.2% | 7.59B YoY-1.7% | ||
| Research & development | 1.01B YoY+1.5% | 998M YoY+4.7% | 953M YoY+872.4% | 98.0M YoY-89.9% | 967M YoY-3.0% | |
| Selling, general & administrative | 1.29B YoY+10.9% | 1.16B YoY-0.1% | 1.16B YoY-1.5% | 1.18B YoY+7.4% | 1.10B YoY-6.3% | |
| General & administrative | 1.29B YoY+10.9% | 1.16B YoY-0.1% | 1.16B YoY-1.5% | 1.18B YoY+7.4% | 1.10B YoY-6.3% | |
| Selling & marketing | 2.69B YoY+5.7% | 2.54B YoY+8.8% | 2.34B YoY+3.1% | 2.27B YoY-6.8% | 2.43B YoY-2.8% | |
| Restructuring | 225M YoY+204.1% | 74.0M YoY-33.3% | 111M YoY-24.0% | 146M YoY+9.8% | 133M YoY+10.8% | |
| Amortization of intangibles | 581M YoY-1.2% | 588M YoY-4.5% | 616M YoY-15.8% | 732M YoY-8.7% | 802M YoY-21.4% | |
| Operating income | 2.16B YoY+811.9% | -303M YoY-170.0% | 433M YoY+119.7% | -2.20B YoY-228.0% | 1.72B YoY+148.0% | |
| Interest expense | 916M YoY-8.6% | 1.00B YoY-2.6% | 1.03B YoY+10.6% | 930M YoY+4.4% | 891M YoY-1.1% | |
| Other non-operating income | -934M YoY+4.8% | -981M YoY+7.2% | -1.06B YoY-9.4% | -966M YoY+8.7% | -1.06B YoY-26.9% | |
| Equity-method income | 15.0M YoY+1400.0% | 1.00M YoY-50.0% | 2.00M YoY-90.5% | 21.0M YoY+133.3% | 9.00M YoY-93.5% | |
| Pre-tax income | 1.22B YoY+195.2% | -1.28B YoY-105.8% | -624M YoY+80.3% | -3.16B YoY-580.7% | 658M YoY+114.9% | |
| Income tax | -180M YoY-126.6% | 676M YoY+9757.1% | -7.00M YoY+98.9% | -643M YoY-404.7% | 211M YoY+225.6% | |
1.41B YoY+186.0% | -1.64B YoY-193.2% | -559M YoY+77.1% | -2.45B YoY-686.6% | 417M YoY+110.5% | ||
$1.21 YoY+183.4% | -$1.45 YoY-190.0% | -$0.50 YoY+77.3% | -$2.20 YoY-678.9% | $0.38 YoY+110.4% | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
13.9B YoY+11.1% | 12.6B YoY+0.5% | 12.5B YoY+3.6% | 12.1B YoY-4.2% | 12.6B YoY-3.3% | ||
40.7B YoY+3.6% | 39.3B YoY-9.6% | 43.5B YoY-1.2% | 44.0B YoY-7.7% | 47.7B YoY-5.9% | ||
13.5B YoY+5.2% | 12.8B YoY+4.5% | 12.2B YoY+6.8% | 11.5B YoY+4.0% | 11.0B YoY-16.2% | ||
32.8B YoY-2.3% | 33.6B YoY-4.9% | 35.4B YoY-0.2% | 35.4B YoY-2.8% | 36.4B YoY-8.0% | ||
7.91B YoY+47.2% | 5.37B YoY-28.4% | 7.51B YoY-3.8% | 7.80B YoY-24.1% | 10.3B YoY+2.5% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
1.65B YoY+32.2% | 1.25B YoY-8.8% | 1.37B YoY-14.0% | 1.59B YoY+99.2% | 798M YoY-34.4% | ||
737M YoY-6.9% | 792M YoY-18.2% | 968M YoY+47.6% | 656M YoY-56.9% | 1.52B YoY+76.5% | ||
-2.15B YoY-20.1% | -1.79B YoY+6.4% | -1.91B YoY-28.6% | -1.49B YoY+31.5% | -2.17B YoY-15.2% | ||
| FX effect on cash | 21.0M YoY+112.1% | -174M YoY-480.0% | -30.0M YoY+75.6% | -123M YoY+3.9% | -128M YoY-1700.0% | |
| Net change in cash | 256M YoY+245.9% | 74.0M YoY-81.2% | 393M YoY-38.2% | 636M YoY+2928.6% | 21.0M YoY-89.6% | |
| Interest paid | 950M YoY-5.4% | 1.00B YoY-6.9% | 1.08B YoY+13.7% | 948M YoY+3.8% | 913M YoY+7.9% | |
| Income taxes paid | — | 471M YoY+58.1% | 298M YoY-45.1% | 543M YoY+9.7% | 495M YoY-30.2% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 35.9B YoY+43.6% | 25.0B YoY+113.5% | 11.7B YoY+15.5% | 10.1B YoY+14.6% | 8.84B YoY-16.5% | |
| P/E | 25.5× | — | — | — | 21.2× | |
| P/S | 2.1× YoY+37.7% | 1.5× YoY+97.1% | 0.8× YoY+14.5% | 0.7× YoY+20.2% | 0.6× YoY-12.4% | |
| P/B | 4.5× YoY-2.5% | 4.7× YoY+175.4% | 1.7× YoY+46.2% | 1.2× YoY+34.4% | 0.9× YoY-18.5% | |
| P/FCF | 31.3× YoY-6.3% | 33.4× YoY+73.3% | 19.2× YoY-2.3% | 19.7× YoY-47.4% | 37.4× YoY+125.8% | |
3.9% | — | — | — | 4.7% | ||
3.2% YoY+6.7% | 3.0% YoY-42.3% | 5.2% YoY+2.4% | 5.1% YoY+90.0% | 2.7% YoY-55.7% | ||
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: TEVA's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TEVA filings on SEC EDGAR → Not investment advice.
